#USA #Glioblastoma #CAR-T therapy #Lexington #Elpis Biopharmaceuticals

Elpis Biopharmaceuticals Presents Cutting-Edge CAR-T Technologies

In a significant stride for cancer treatment, Elpis Biopharmaceuticals, a clinical-stage cell therapy company, is set to unveil its groundbreaking CAR-T cell therapy technologies during the American Association for Cancer Research (AACR) Annual Meeting in 2025. The company will present two impactful late-breaking posters showcasing the potential of its bispecific armored CAR-T therapies to effectively combat solid tumors and glioblastoma (GBM).

Late-Breaking Presentations

The first poster, LB363, highlights a pioneering human B7H3 CAR-T therapy, designated EPC-002. Research results indicate that this innovative therapy has been designed with a unique multi-mechanism armor that allows it to overcome multiple resistance mechanisms present in the tumor microenvironment (TME). The overexpression of B7H3 in a myriad of solid tumors—namely skin, pancreatic, lung, breast, colon, kidney, and ovarian cancers—makes it a prime target for this therapy. Through preclinical mouse studies, EPC-002 demonstrated remarkable efficacy by achieving complete tumor regression while using an exceptionally low dose of CAR-T cells.

The second poster, LB360, focuses on the ongoing development of EPC-003, a first-in-class bispecific CAR-T therapy that targets both IL13Ra2 and B7H3 antigens frequently found in GBM tumors. Utilizing Elpis’s proprietary engineering platforms, EPC-003 aims to enhance the persistence of CAR-T cells, block immune suppression, and penetrate the blood-brain barrier (BBB) to achieve significant therapeutic results. Early data presented at AACR showed promising outcomes regarding tumor regression following the intracranial injection of these CAR-T cells into GBM models.

Expert Insights

Yan Chen, CEO of Elpis Biopharmaceuticals, expressed optimism regarding the validation these late-breaking presentations represent: “Having two presentations detailing our lead product candidates accepted at AACR is tremendous validation of Elpis's technologies and the potential that each offers in the treatment of solid tumors and glioblastoma.” The company’s innovative approach not only addresses the established challenges of tumor microenvironment resistance but also aims to tackle the antigen heterogeneity that typically complicates treatment for patients with solid tumors.

Chen added, “We are enthusiastic about advancing each product into clinical trials, including a proof-of-concept study for EPC-003 in patients with resistant or relapsed glioblastoma.”

Presentation Details

Both presentations will occur on April 29, 2025, during the Late-Breaking Research Clinical session:

• - LB363: - Multi-mechanism human B7H3 CAR-T effectively overcome tumor microenvironment resistance in treatment of solid tumors - Poster Section 53, Board Number 7 (2:00 PM - 5:00 PM)
• - LB360: - Discovery and development of fully human IL13Ra2/B7H3 bispecific armored CAR-T for treatment of glioblastoma - Poster Section 53, Board Number 4 (2:00 PM - 5:00 PM)

About Elpis Biopharmaceuticals

Elpis Biopharmaceuticals is at the forefront of developing next-generation cell therapies aimed at solid tumors. Its robust pipeline aims to offer first- and best-in-class bispecific armored CAR-T therapies capable of surmounting the challenges posed by tumor heterogeneity and immunosuppressive environments. Through innovative platforms—including multi-mechanism armor technology and rapid mRNA display discovery—the company's lead programs, EPC-003 and EPC-002, target glioblastoma and a range of solid tumors, respectively. Headquartered in Lexington, MA, and Singapore, Elpis Biopharmaceuticals continues to push the boundaries of what is possible in cancer therapy. For further information, visit www.elpisbiopharmaceuticals.com.